Allogene Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Allogene Therapeutics, Inc. (ALLO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 54.56 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 55.05M shares, a 7.05% increase year-over-year.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 51.42M shares, a 32.83% increase year-over-year.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 38.71M shares, a 0.61% increase year-over-year.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 38.48M shares, a 63.30% increase year-over-year.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 48.98M shares, a 24.17% increase from fiscal 2024.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 39.44M shares, a 8.98% increase from fiscal 2023.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 36.19M shares, a 48.97% increase from fiscal 2022.
- Allogene Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 24.29M shares, a 41.16% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 54.56M shares 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | 55.05M shares 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | 48.98M shares 10-K · filed 2026-03-12 | ||||||
| 2025-09-30 | 48.89M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 50.89M shares 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | 51.42M shares 10-Q · filed 2026-05-13 | ||||||
| 2024-12-31 | 39.44M shares 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | 38.37M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 38.23M shares 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | 38.71M shares 10-Q · filed 2025-05-13 | ||||||
| 2023-12-31 | 36.19M shares 10-K · filed 2025-03-13 | ||||||
| 2023-09-30 | 35.51M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 36.61M shares 10-Q · filed 2024-08-07 | ||||||
| 2023-03-31 | 38.48M shares 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | 24.29M shares 10-K/A · filed 2024-03-14 | ||||||
| 2022-09-30 | 25.14M shares 10-Q · filed 2023-11-02 | ||||||
| 2022-06-30 | 25.92M shares 10-Q · filed 2023-08-02 | ||||||
| 2022-03-31 | 23.56M shares 10-Q · filed 2023-05-03 | ||||||
| 2021-12-31 | 17.21M shares 10-K/A · filed 2024-03-14 | ||||||
| 2021-09-30 | 17.87M shares 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | 19.67M shares 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | 21.90M shares 10-Q · filed 2022-05-04 | ||||||
| 2020-12-31 | 22.55M shares 10-K/A · filed 2024-03-14 | ||||||
| 2020-09-30 | 24.64M shares 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 26.72M shares 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | 29.18M shares 10-Q · filed 2021-05-05 | ||||||
| 2019-12-31 | 27.95M shares 10-K · filed 2022-02-23 | ||||||
| 2019-09-30 | 29.88M shares 10-Q · filed 2020-11-04 | ||||||
| 2019-06-30 | 31.18M shares 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | 33.50M shares 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | 32.09M shares 10-K · filed 2021-02-25 | 31.94M shares 10-K · filed 2019-03-08 | |||||
| 2018-09-30 | 101.81B shares 10-Q · filed 2018-11-21 | 101.81M shares 10-Q · filed 2019-11-05 | 101.81B shares 10-Q · filed 2018-11-21 | ||||
| 2018-06-30 | 43.27M shares 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | 0.00 shares 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |